Filana Therapeutics Q2 2026 Financials: Cash Down, Litigation Costs Falling
Filana Therapeutics reported $82.7 million in cash at Q2 2026, down from $95.5 million in Q4 2025, driven by R&D and G&A reductions while litigation settlement funds were moved to escrow.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day